-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biotech company Modelna today announced a supply agreement with the UK government to provide an additional 2 million doses of the COVID-19 candidate vaccine (mRNA-1273), which will begin shipping to the UK in March 2021.
uk government has now received 7 million doses of mRNA-1273.
, chief executive of Moderna, said: "We are grateful for our partnership with the UK government and many other governments and other key partners around the world.
Moderna has invested in the creation and development of a new platform for the design and manufacture of new mRNA-based vaccines.
we are proud of the progress made in mRNA-1273, including the results from the PHASE III COVE study."
November 16, Moderna announced that the NIH-appointed Independent Data Security Monitoring Committee (DSMB) phase III study of COVID-19 candidate vaccine mRNA-1273 had informed Moderna that the trial had reached the main end of the study, with a vaccine efficacy of 94.5%.
study, called COVE, recruited more than 30,000 participants in the United States and was conducted in collaboration with the National Institutes of Health (NIH) National Institutes of Allergy and Infectious Diseases (NIAID).
。
